Gossamer Bio, Inc. received a letter from Nasdaq confirming it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. This resolves the non-compliance notice issued on April 8, 2026, which cited a failure to maintain a $1.00 minimum bid price for 30 consecutive business days. The company previously executed a 1-for-80 reverse stock split effective September 10, 2026, with adjusted trading beginning September 11, 2026. Gossamer Bio operates in the biotechnology industry, focusing on the discovery and development of therapies for cancer and inflammatory diseases.
